Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | HNF4A | P41235 | 1/20 | 0.44 |
| ▸ | HK1 | P19367 | 1/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395494 | 0.82 | MAPT (0.56) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7614948 | 0.79 | ALDH1A1 (0.56) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4529250 | 0.79 | BCAT2 (0.61) | BCAT2MEN1KMT2ASMN1; SMN2CHRNB2 | |
| SCHEMBL11309513 | 0.76 | BCAT2 (0.57) | BCAT2MEN1KMT2ASMN1; SMN2CHRNB2 | |
| SCHEMBL22445691 | 0.76 | BCAT2 (0.62) | BCAT2MEN1KMT2ASMN1; SMN2CHRNB2 | |
| SCHEMBL16581129 | 0.76 | BCAT2 (0.57) | BCAT2MEN1KMT2ASMN1; SMN2CHRNB2 | |
| SCHEMBL30505632 | 0.76 | BCAT2 (0.57) | BCAT2MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL3876724 | 0.76 | BCAT2 (0.57) | BCAT2MEN1KMT2ASMN1; SMN2CHRNB2 | |
| SCHEMBL3420505 | 0.76 | BCAT2 (0.57) | BCAT2MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL9219604 | 0.76 | BCAT2 (0.57) | BCAT2MEN1KMT2ASMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969741-B2 | Pyrazolotriazines as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2018-05-15 | — | — | US | disclosed |
| US-9969741-B2 | Pyrazolotriazines as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2018-05-15 | — | — | US | disclosed |
| EP-2957562-B1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2017-12-20 | — | — | EP | disclosed |
| US-20170197966-A1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2017-07-13 | — | — | US | disclosed |
| US-20170197966-A1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2017-07-13 | — | — | US | disclosed |
| EP-2957562-A1 | Pyrazolotriazines as inhibitors of nucleases | Masarykova univerzita (CZ) | 2015-12-23 | — | — | EP | disclosed |
| WO-2015192817-A1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2015-12-23 | — | — | WO | disclosed |
| EP-2069351-B1 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBVIE INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8183250-B2 | Potent PARP inhibitors | ABBOTT LABORATORIES (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090298858-A1 | POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2069351-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080015182-A1 | Potent PARP Inhibitors | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | disclosed |
| WO-2007149907-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298858-A1 | POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | BCAT2 2154/4885MEN1 3112/4885KMT2A 512/4885 |
| US-20080015182-A1 | Potent PARP Inhibitors | PARP1, PARP2, PARP3 | BCAT2 2154/4885MEN1 3112/4885KMT2A 512/4885 |
| US-20170197966-A1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | DNASE1, TDP1, RNASEH1 | BCAT2 4330/4885MEN1 1412/4885KMT2A 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.